Answers are grounded in this paper and cite their sources.
Although no nebulized, dual mechanism, long-acting bronchodilator is currently marketed, with the approval of once-daily long-acting muscarinic antagonist (LAMA) revefenacinefenacin, it is theoretically possible to deliver a LAMA and long-acting beta2-agonist via standard jet nebulizer. The primary
No takes yet. Share an insight, caveat, or question.
Siler et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: